💊 Препараты А-Я 🧬 Мишени 🛠 Инструменты 📚 Руководства
Все препараты Классы препаратов Терапевтические области Побочные Эффекты
Руководства Глоссарий Хронология
Сравнения Путешествия препаратов Группы лекарственных средств
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Xanomeline Tartrate

CHEMBL2336050 Phase 4 Одобрено Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
431.5 g/mol
LogP
—
Phase
4

Xanomeline tartrate is the tartrate salt form of xanomeline, a selective M1/M4 muscarinic receptor agonist being developed for schizophrenia and Alzheimer's disease. The tartrate salt form is used in the combination product with trospium chloride (KarXT/Cobenfy), where xanomeline provides central therapeutic muscarinic agonism while trospium blocks peripheral muscarinic receptors to reduce gastrointestinal side effects. This combination approach enables effective central muscarinic activation with an acceptable safety profile.

Молекулярная масса

431,5000 g/mol

TPSA

182,00 Ų

Терапевтические области

Alzheimer's Disease Schizophrenia Bipolar Disorder

Механизм действия

Binds to and activates its target receptor, mimicking the action of the endogenous ligand to produce a specific physiological response.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Механизм

Binds to and activates its target receptor, mimicking the action of the endogenous ligand to produce a specific physiological response.

2D Структура

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
CCCCCCOc1nsnc1C1=CCCN(C)C1.O=C(O)C(O)C(O)C(=O)O

                

                

                
                

                    
InChI

                    
InChI=1S/C14H23N3OS.C4H6O6/c1-3-4-5-6-10-18-14-13(15-19-16-14)12-8-7-9-17(2)11-12;5-1(3(7)8)2(6)4(9)10/h8H,3-7,9-11H2,1-2H3;1-2,5-6H,(H,7,8)(H,9,10)

                

                

                

                    
                    

                        
Molecular Formula

                        
C18H29N3O7S

                    

                    
                    

                        
HBD / HBA

                        
4 / 11

                    

                    
                    

                        
Вращаемые Связи

                        
10

                    

                    
                    
                    

                        
Тяжёлые Атомы

                        
29

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Часто задаваемые вопросы

                

                    
                    

                        
                        

                            
Xanomeline tartrate is the tartrate salt form of xanomeline, a selective M1/M4 muscarinic receptor agonist being developed for schizophrenia and Alzheimer's disease. The tartrate salt form is used in the combination product with trospium chloride (KarXT/Cobenfy), where xanomeline provides central therapeutic muscarinic agonism while trospium blocks peripheral muscarinic receptors to reduce gastrointestinal side effects. This combination approach enables effective central muscarinic activation with an acceptable safety profile.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Binds to and activates its target receptor, mimicking the action of the endogenous ligand to produce a specific physiological response.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Xanomeline Tartrate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL2336050.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 71456.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
Медицинский отказ от ответственности

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.